Premium
5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia
Author(s) -
McCoy J.,
Cadegiani F.A.,
Wambier C.G.,
Herrera S.,
VañoGalván S.,
Mesinkovska N.A.,
Ramos P.M.,
Shapiro J.,
Sinclair R.,
Tosti A.,
Goren A.
Publication year - 2021
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.17021
Subject(s) - medicine , 5 alpha reductase inhibitor , dutasteride , covid-19 , cohort , finasteride , retrospective cohort study , disease , cancer , prostate cancer , infectious disease (medical specialty) , prostate
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom